XPHYF News and Press, XPhyto Therapeutics Corp From 04/20/20

VANCOUVER, BC / ACCESSWIRE / April 20, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY / FSE:4XT / OTC PINK:XPHYF) ("XPhyto" or the "Company") is pleased to announce that it has signed a definitive development, technology purchase and licence agreement (the "Agreement") with 3a-Diagnostics GmbH ...

VANCOUVER, BC / ACCESSWIRE / March 25, 2020 / XPhyto Therapeutics Corp. (CSE:XPHY) (FSE:4XT) (OTC PINK:XPHYF) ("XPhyto" or the "Company") is pleased to announce that an exclusive infectious disease advisory agreement (the "Agreement") has been signed between XPhyto and Prof. Dr. Wolfgang Ei...

Vancouver, British Columbia--(Newsfile Corp. - March 23, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemi...

Vancouver, British Columbia--(Newsfile Corp. - March 20, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemi...

Vancouver, British Columbia--(Newsfile Corp. - March 19, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) ("XPhyto" or the "Company") is pleased to announce significant progress with respect to development of its cannabidiol ("CBD") based Epilepsy product. Further to the...